Clinical and hematologic characteristics of MDS patients administered EPO plus ATRA
| Patient no. . | Age (y) . | Sex . | FAB subtype . | MDS duration (mo) . | Baseline serum EPO (mIU/mL) . | RBC transfusions . | Hb (g/dL)* . | Erythroid response . | ANC (× 109/L)* . | Neutrophil response . | Platelets (× 109/qL)* . | Platelet response . | Karyotype . | IPSS score value . | IPSS risk group . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | Before . | At 6 wks . | At 12 wks . | Before . | At 12 wks . | Before . | At 12 wks . | ||||||||||||
| 1 | 61 | M | RA | 25 | 513 | 3 | 1 | 7.9 | 7.3 | 8.2 | MiR | 2.5 | 2.7 | NA | 93 | 158 | MaR | Good | 0.5 | Int-1 |
| 2 | 64 | M | RA | 47 | 673 | 2 | 2 | 8.4 | 7.9 | 8.5 | NR | 1.7 | 1.6 | NA | 145 | 175 | NA | Good | 0 | Low |
| 3 | 57 | F | RA | 12 | 281 | 0 | 0 | 8.5 | 10.9 | 11.3 | MaR | 2.6 | 4.4 | NA | 214 | 266 | NA | ND | NA | NA |
| 4 | 52 | M | RA | 15 | 374 | 0 | 0 | 8.6 | 8.3 | 8.0 | NR | 1.3 | 1.2 | NR | 131 | 115 | NA | Good | 0.5 | Int-1 |
| 5 | 62 | M | RA | 38 | 586 | 4 | 2 | 7.4 | 8.1 | 7.9 | MiR | 0.5 | 1.2 | MaR | 54 | 121 | MaR | Good | 0.5 | Int-1 |
| 6 | 75 | F | RA | 56 | ND | 2 | 1 | 7.7 | 7.8 | 8.6 | MiR | 3.3 | 2.9 | NA | 168 | 238 | NA | Int | 0.5 | Int-1 |
| 7 | 78 | M | RARS | 23 | 938 | 3 | 2 | 6.1 | 6.4 | 6.6 | NR | 1.9 | 2.1 | NA | 151 | 191 | NA | ND | NA | NA |
| 8 | 77 | F | RA | 18 | 1115 | 2 | 0 | 7.2 | 8.5 | 8.3 | MaR | 2.4 | 2.2 | NA | 220 | 246 | NA | Good | 0 | Low |
| 9 | 56 | M | RA | 44 | 231 | 2 | 2 | 8.1 | 8.7 | 7.8 | NR | 0.9 | 1.2 | NR | 84 | 75 | NR | Int | 1 | Int-1 |
| 10 | 73 | F | RAEB | 33 | 125 | 0 | 0 | 9.5 | 9.3 | 10.1 | NR | 1.4 | 1.5 | NR | 136 | 163 | NA | Int | 1.5 | Int-1 |
| 11 | 71 | M | RA | 51 | 80 | 2 | 1 | 8.6 | 8.7 | 9.5 | MiR | 3.2 | 3.5 | NA | 117 | 191 | NA | ND | NA | NA |
| 12 | 68 | F | RA | 55 | 1482 | 4 | 4 | 6.3 | 6.1 | 6.6 | NR | 1.2 | 1.5 | NR | 298 | 263 | NA | ND | NA | NA |
| 13 | 54 | F | RAEB | 21 | 363 | 2 | 1 | 8.5 | 8.1 | 8.8 | MiR | 1.9 | 2.4 | NA | 201 | 152 | NA | Int | 1 | Int-1 |
| 14 | 72 | M | RARS | 9 | ND | 3 | 3 | 7.4 | 8.3 | 8.1 | NR | 2.1 | 3.2 | NA | 85 | 77 | NR | ND | NA | NA |
| 15 | 62 | F | RA | 15 | 269 | 0 | 0 | 9.3 | 11.4 | 11.6 | MaR | 3.7 | 4.1 | NA | 104 | 123 | NA | ND | NA | NA |
| 16 | 69 | M | RAEB | 16 | 181 | 0 | 0 | 8.6 | 9.1 | 9.7 | MiR | 1.3 | 3.5 | MaR | 32 | 53 | MiR | Poor | 2 | Int-2 |
| 17 | 76 | F | RA | 52 | ND | 2 | 2 | 8.3 | 9.0 | 8.7 | NR | 1.0 | 1.8 | MaR | 102 | 92 | NA | Good | 0.5 | Int-1 |
| 18 | 70 | F | RA | 47 | 135 | 3 | 0 | 7.6 | 9.6 | 10.9 | MaR | 3.1 | 4.3 | NA | 74 | 166 | MaR | ND | NA | NA |
| 19 | 64 | M | RA | 18 | 560 | 3 | 2 | 8.1 | 8.6 | 8.4 | NR | 2.3 | 2.1 | NA | 126 | 295 | NA | Good | 0 | Low |
| 20 | 77 | F | RARS | 31 | 175 | 0 | 0 | 9.1 | 10.0 | 9.8 | NR | 4.1 | 4.4 | NA | 229 | 247 | NA | Good | 0 | Low |
| 21 | 68 | F | RA | 27 | ND | 3 | 3 | 7.9 | 7.5 | 8.1 | NR | 2.0 | 2.6 | NA | 141 | 173 | NA | Int | 0.5 | Int-1 |
| 22 | 66 | F | RAEB | 19 | 658 | 2 | 1 | 6.7 | 8.0 | 7.8 | MiR | 1.1 | 2.7 | MaR | 158 | 179 | NA | Good | 1 | Int-1 |
| 23 | 61 | M | RA | 34 | 165 | 2 | 0 | 8.1 | 9.3 | 9.5 | MiR | 1.4 | 3.1 | MaR | 86 | 137 | MaR | Int | 1 | Int-1 |
| 24 | 70 | F | RA | 13 | 273 | 0 | 0 | 8.5 | 8.2 | 8.7 | NR | 2.3 | 2.0 | NA | 147 | 128 | NA | Good | 0 | Low |
| 25 | 63 | F | RA | 8 | ND | 3 | 2 | 6.9 | 7.3 | 8.0 | NR | 0.9 | 0.7 | NR | 131 | 126 | NA | Good | 0.5 | Int-1 |
| 26 | 72 | M | RA | 22 | 838 | 2 | 0 | 7.1 | 8.6 | 10.4 | MaR | 1.3 | 1.6 | NR | 93 | 145 | MaR | Good | 0.5 | Int-1 |
| 27 | 74 | M | RAEB | 9 | 715 | 3 | 3 | 6.8 | 7.3 | 7.5 | NR | 1.0 | 0.8 | NR | 67 | 78 | NR | ND | NA | NA |
| Patient no. . | Age (y) . | Sex . | FAB subtype . | MDS duration (mo) . | Baseline serum EPO (mIU/mL) . | RBC transfusions . | Hb (g/dL)* . | Erythroid response . | ANC (× 109/L)* . | Neutrophil response . | Platelets (× 109/qL)* . | Platelet response . | Karyotype . | IPSS score value . | IPSS risk group . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | Before . | At 6 wks . | At 12 wks . | Before . | At 12 wks . | Before . | At 12 wks . | ||||||||||||
| 1 | 61 | M | RA | 25 | 513 | 3 | 1 | 7.9 | 7.3 | 8.2 | MiR | 2.5 | 2.7 | NA | 93 | 158 | MaR | Good | 0.5 | Int-1 |
| 2 | 64 | M | RA | 47 | 673 | 2 | 2 | 8.4 | 7.9 | 8.5 | NR | 1.7 | 1.6 | NA | 145 | 175 | NA | Good | 0 | Low |
| 3 | 57 | F | RA | 12 | 281 | 0 | 0 | 8.5 | 10.9 | 11.3 | MaR | 2.6 | 4.4 | NA | 214 | 266 | NA | ND | NA | NA |
| 4 | 52 | M | RA | 15 | 374 | 0 | 0 | 8.6 | 8.3 | 8.0 | NR | 1.3 | 1.2 | NR | 131 | 115 | NA | Good | 0.5 | Int-1 |
| 5 | 62 | M | RA | 38 | 586 | 4 | 2 | 7.4 | 8.1 | 7.9 | MiR | 0.5 | 1.2 | MaR | 54 | 121 | MaR | Good | 0.5 | Int-1 |
| 6 | 75 | F | RA | 56 | ND | 2 | 1 | 7.7 | 7.8 | 8.6 | MiR | 3.3 | 2.9 | NA | 168 | 238 | NA | Int | 0.5 | Int-1 |
| 7 | 78 | M | RARS | 23 | 938 | 3 | 2 | 6.1 | 6.4 | 6.6 | NR | 1.9 | 2.1 | NA | 151 | 191 | NA | ND | NA | NA |
| 8 | 77 | F | RA | 18 | 1115 | 2 | 0 | 7.2 | 8.5 | 8.3 | MaR | 2.4 | 2.2 | NA | 220 | 246 | NA | Good | 0 | Low |
| 9 | 56 | M | RA | 44 | 231 | 2 | 2 | 8.1 | 8.7 | 7.8 | NR | 0.9 | 1.2 | NR | 84 | 75 | NR | Int | 1 | Int-1 |
| 10 | 73 | F | RAEB | 33 | 125 | 0 | 0 | 9.5 | 9.3 | 10.1 | NR | 1.4 | 1.5 | NR | 136 | 163 | NA | Int | 1.5 | Int-1 |
| 11 | 71 | M | RA | 51 | 80 | 2 | 1 | 8.6 | 8.7 | 9.5 | MiR | 3.2 | 3.5 | NA | 117 | 191 | NA | ND | NA | NA |
| 12 | 68 | F | RA | 55 | 1482 | 4 | 4 | 6.3 | 6.1 | 6.6 | NR | 1.2 | 1.5 | NR | 298 | 263 | NA | ND | NA | NA |
| 13 | 54 | F | RAEB | 21 | 363 | 2 | 1 | 8.5 | 8.1 | 8.8 | MiR | 1.9 | 2.4 | NA | 201 | 152 | NA | Int | 1 | Int-1 |
| 14 | 72 | M | RARS | 9 | ND | 3 | 3 | 7.4 | 8.3 | 8.1 | NR | 2.1 | 3.2 | NA | 85 | 77 | NR | ND | NA | NA |
| 15 | 62 | F | RA | 15 | 269 | 0 | 0 | 9.3 | 11.4 | 11.6 | MaR | 3.7 | 4.1 | NA | 104 | 123 | NA | ND | NA | NA |
| 16 | 69 | M | RAEB | 16 | 181 | 0 | 0 | 8.6 | 9.1 | 9.7 | MiR | 1.3 | 3.5 | MaR | 32 | 53 | MiR | Poor | 2 | Int-2 |
| 17 | 76 | F | RA | 52 | ND | 2 | 2 | 8.3 | 9.0 | 8.7 | NR | 1.0 | 1.8 | MaR | 102 | 92 | NA | Good | 0.5 | Int-1 |
| 18 | 70 | F | RA | 47 | 135 | 3 | 0 | 7.6 | 9.6 | 10.9 | MaR | 3.1 | 4.3 | NA | 74 | 166 | MaR | ND | NA | NA |
| 19 | 64 | M | RA | 18 | 560 | 3 | 2 | 8.1 | 8.6 | 8.4 | NR | 2.3 | 2.1 | NA | 126 | 295 | NA | Good | 0 | Low |
| 20 | 77 | F | RARS | 31 | 175 | 0 | 0 | 9.1 | 10.0 | 9.8 | NR | 4.1 | 4.4 | NA | 229 | 247 | NA | Good | 0 | Low |
| 21 | 68 | F | RA | 27 | ND | 3 | 3 | 7.9 | 7.5 | 8.1 | NR | 2.0 | 2.6 | NA | 141 | 173 | NA | Int | 0.5 | Int-1 |
| 22 | 66 | F | RAEB | 19 | 658 | 2 | 1 | 6.7 | 8.0 | 7.8 | MiR | 1.1 | 2.7 | MaR | 158 | 179 | NA | Good | 1 | Int-1 |
| 23 | 61 | M | RA | 34 | 165 | 2 | 0 | 8.1 | 9.3 | 9.5 | MiR | 1.4 | 3.1 | MaR | 86 | 137 | MaR | Int | 1 | Int-1 |
| 24 | 70 | F | RA | 13 | 273 | 0 | 0 | 8.5 | 8.2 | 8.7 | NR | 2.3 | 2.0 | NA | 147 | 128 | NA | Good | 0 | Low |
| 25 | 63 | F | RA | 8 | ND | 3 | 2 | 6.9 | 7.3 | 8.0 | NR | 0.9 | 0.7 | NR | 131 | 126 | NA | Good | 0.5 | Int-1 |
| 26 | 72 | M | RA | 22 | 838 | 2 | 0 | 7.1 | 8.6 | 10.4 | MaR | 1.3 | 1.6 | NR | 93 | 145 | MaR | Good | 0.5 | Int-1 |
| 27 | 74 | M | RAEB | 9 | 715 | 3 | 3 | 6.8 | 7.3 | 7.5 | NR | 1.0 | 0.8 | NR | 67 | 78 | NR | ND | NA | NA |
NA indicates not applicable; ND, not done; Int, intermediate.
Blood counts before and after treatment were calculated by averaging the results of 3 counts taken in a 2-week period.